Dong-A ST (Dong-A ST) announced on the 2nd that its first-quarter performance this year recorded sales of 140.062 billion KRW and an operating profit of 735 million KRW. Compared to the same period last year, sales increased by 3.7%, but operating profit decreased by 89.0%.
The company explained, "Sales increased due to growth in the ethical drugs (ETC) and overseas business sectors," adding, "Operating profit decreased due to increased research and development (R&D) expenses."
In the ETC sector, although sales of some prescription drug items declined, sales increased by 0.6% year-on-year to 101.6 billion KRW as the growth hormone product Grotrophin grew. The overseas business sector also grew by 16.6% year-on-year due to increased sales of Canbakkas in the Cambodia region.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
